{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-056497","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2026-08-13T12:32:09+00:00","discovered_at":"2026-08-13T12:35:00.374875+00:00","generated_at":"2026-08-13T12:35:09.213486+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ovid Q2 2026 net loss $15M; soticlestat rights sold to Perceptive NewCo for up to $294.5M milestones","bullets":["Cash $169.8M at June 30, 2026; runway into 2029.","Net loss $15.0M ($0.08/share) vs $4.7M ($0.06) in Q2 2025; R&D spend up to $10.0M.","OV329 Phase 2 FOS study initiated; photosensitivity study testing 5/7/9 mg doses, results near year-end 2026.","Soticlestat global rights assigned to Perceptive NewCo; Ovid eligible for up to $294.5M milestones plus low-to-mid single-digit royalties.","Leadership: Kevin Norrett CBO, Charles Carter CFO, Eliseo Salinas R&D Advisor; warrants exercised for ~$53.9M proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-056497","json":"https://secwatch.observer/filing/0001628280-26-056497.json","markdown":"https://secwatch.observer/filing/0001628280-26-056497.md","text":"https://secwatch.observer/filing/0001628280-26-056497.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828026056497/0001628280-26-056497-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828026056497/ovid-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T12:35:09.213486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}